In addition, we validated the effects of C8018‐7840 in hepatocellular carcinoma (SNU‐449 and PLC), pancreatic ductal carcinoma (PANC‐1 and SUIT‐2), and breast cancer (MDA‐MB‐231 and MCF‐7) under CCL18 treatment. This evidence concerns the gene HSPG2 and breast cancer.